Drugs / UDP-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06813339 | Feb 2025 → Dec 2026 expected | acute coronary syndrome, atherosclerotic cardiovascular disease | Cyclarity Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UDP-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06813339 ↗ |
| Route | Intravenous | “administered as intravenous (IV) bolus push injection” NCT06813339 ↗ |